Galectin Therapeutics Inc. (GALT)

Pharmaceutical Preparations · market cap $408M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-13 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Galectin Therapeutics (GALT) is a clinical-stage pharmaceutical company with 15 employees and a $267M market cap, built around belapectin, a Phase 3 asset targeting prevention of esophageal varices in cirrhotic patients. The company carries no revenue, roughly 11 months of cash runway at current burn, and a history of $30–47M annual net losses driven by R&D spend.

The catalyst path

2026-11-13 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
GR-MD-02	Phase 2	Psoriasis
belapectin	Phase 3	Prevention of Esophageal Varices

Price & technical context

3-month

-16.6%

6-month

+40.3%

12-month

-11.3%

52-wk range

$2.08–$6.51

vs 50-day MA

+1.3%

vs 200-day MA

+14.7%

Realized vol

92.0%

Max drawdown

-72.0%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for GALT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.